The global hemoglobinopathy drugs market is expected to grow at a CAGR of 5.5% during the forecast period, from 2021 to 2030. The market is driven by factors such as increasing prevalence of sickle cell disease and thalassemia, rising awareness about the condition, and growing number of patients with chronic anemia. The global hemoglobinopathy drugs market is segmented on the basis of type into hydroxyurea, glutamine, and zynteglo; on the basis of application into sickle cell diseases and thalassemia; and on the basis of region into North America, Latin America, Europe, Asia Pacific (APAC), Middle East & Africa (MEA). The hydroxyurea segment accounted for a significant share in 2018 owing to its efficacy in treating sickle cell disease. Glutamine has been gaining traction owing to its ability to treat anemia caused by chronic kidney disease or cancer chemotherapy. Zynteglo has been gaining traction owing to its ability to treat iron deficiency anemia caused by chronic kidney disease or cancer chemotherapy.
Some Of The Growth Factors Of This Market:
- Increasing prevalence of anemia and other blood disorders in the elderly population is expected to drive the Hemoglobinopathy Drugs market.
- Increasing awareness about the benefits of Hemoglobinopathy Drugs for treating anemia and other blood disorders is expected to drive the Hemoglobinopathy Drugs market.
- Increasing number of clinical trials on new drugs for treating anemia and other blood disorders are expected to fuel the growth of the Hemoglobinopathy Drugs market.
- Growing focus on research and development activities by major players in this industry is also driving growth.
Industry Growth Insights published a new data on “Hemoglobinopathy Drugs Market”. The research report is titled “Hemoglobinopathy Drugs Market research by Types (Hydroxyurea, Glutamine, Zynteglo, Other), By Applications (Sickle Cell Diseases, Thalassemia), By Players/Companies Novartis, AstraZeneca, Bluebird, Bristol-Myers Squibb, Emmaus Medical, Acceleron Pharma, HemaQuest Pharmaceuticals, Eli Lilly and Company, Celgene”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Hemoglobinopathy Drugs Market Research Report
By Type
Hydroxyurea, Glutamine, Zynteglo, Other
By Application
Sickle Cell Diseases, Thalassemia
By Companies
Novartis, AstraZeneca, Bluebird, Bristol-Myers Squibb, Emmaus Medical, Acceleron Pharma, HemaQuest Pharmaceuticals, Eli Lilly and Company, Celgene
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
231
Number of Tables & Figures
162
Customization Available
Yes, the report can be customized as per your need.
Global Hemoglobinopathy Drugs Market Report Segments:
The global Hemoglobinopathy Drugs market is segmented on the basis of:
Types
Hydroxyurea, Glutamine, Zynteglo, Other
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Sickle Cell Diseases, Thalassemia
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Novartis
- AstraZeneca
- Bluebird
- Bristol-Myers Squibb
- Emmaus Medical
- Acceleron Pharma
- HemaQuest Pharmaceuticals
- Eli Lilly and Company
- Celgene
Highlights of The Hemoglobinopathy Drugs Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Hydroxyurea
- Glutamine
- Zynteglo
- Other
- By Application:
- Sickle Cell Diseases
- Thalassemia
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Hemoglobinopathy Drugs Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Hemoglobinopathy drugs are medications that help to treat hemoglobinopathies. Hemoglobinopathies are disorders of the blood's ability to carry oxygen. These disorders can cause serious health problems, including anemia and death. Hemoglobinopathy drugs help to improve the flow of oxygenated blood throughout the body and may help to prevent or reduce symptoms associated with hemoglobinopathies.
Some of the major companies in the hemoglobinopathy drugs market are Novartis, AstraZeneca, Bluebird, Bristol-Myers Squibb, Emmaus Medical, Acceleron Pharma, HemaQuest Pharmaceuticals, Eli Lilly and Company, Celgene.
The hemoglobinopathy drugs market is expected to grow at a compound annual growth rate of 5.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Hemoglobinopathy Drugs Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Hemoglobinopathy Drugs Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Hemoglobinopathy Drugs Market - Supply Chain
4.5. Global Hemoglobinopathy Drugs Market Forecast
4.5.1. Hemoglobinopathy Drugs Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Hemoglobinopathy Drugs Market Size (000 Units) and Y-o-Y Growth
4.5.3. Hemoglobinopathy Drugs Market Absolute $ Opportunity
5. Global Hemoglobinopathy Drugs Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Hemoglobinopathy Drugs Market Size and Volume Forecast by Type
5.3.1. Hydroxyurea
5.3.2. Glutamine
5.3.3. Zynteglo
5.3.4. Other
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Hemoglobinopathy Drugs Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Hemoglobinopathy Drugs Market Size and Volume Forecast by Application
6.3.1. Sickle Cell Diseases
6.3.2. Thalassemia
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Hemoglobinopathy Drugs Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Hemoglobinopathy Drugs Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Hemoglobinopathy Drugs Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Hemoglobinopathy Drugs Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Hemoglobinopathy Drugs Demand Share Forecast, 2019-2026
9. North America Hemoglobinopathy Drugs Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Hemoglobinopathy Drugs Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Hemoglobinopathy Drugs Market Size and Volume Forecast by Application
9.4.1. Sickle Cell Diseases
9.4.2. Thalassemia
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Hemoglobinopathy Drugs Market Size and Volume Forecast by Type
9.7.1. Hydroxyurea
9.7.2. Glutamine
9.7.3. Zynteglo
9.7.4. Other
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Hemoglobinopathy Drugs Demand Share Forecast, 2019-2026
10. Latin America Hemoglobinopathy Drugs Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Hemoglobinopathy Drugs Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Hemoglobinopathy Drugs Market Size and Volume Forecast by Application
10.4.1. Sickle Cell Diseases
10.4.2. Thalassemia
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Hemoglobinopathy Drugs Market Size and Volume Forecast by Type
10.7.1. Hydroxyurea
10.7.2. Glutamine
10.7.3. Zynteglo
10.7.4. Other
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Hemoglobinopathy Drugs Demand Share Forecast, 2019-2026
11. Europe Hemoglobinopathy Drugs Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Hemoglobinopathy Drugs Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Hemoglobinopathy Drugs Market Size and Volume Forecast by Application
11.4.1. Sickle Cell Diseases
11.4.2. Thalassemia
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Hemoglobinopathy Drugs Market Size and Volume Forecast by Type
11.7.1. Hydroxyurea
11.7.2. Glutamine
11.7.3. Zynteglo
11.7.4. Other
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Hemoglobinopathy Drugs Demand Share, 2019-2026
12. Asia Pacific Hemoglobinopathy Drugs Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Hemoglobinopathy Drugs Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Hemoglobinopathy Drugs Market Size and Volume Forecast by Application
12.4.1. Sickle Cell Diseases
12.4.2. Thalassemia
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Hemoglobinopathy Drugs Market Size and Volume Forecast by Type
12.7.1. Hydroxyurea
12.7.2. Glutamine
12.7.3. Zynteglo
12.7.4. Other
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Hemoglobinopathy Drugs Demand Share, 2019-2026
13. Middle East & Africa Hemoglobinopathy Drugs Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Hemoglobinopathy Drugs Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Hemoglobinopathy Drugs Market Size and Volume Forecast by Application
13.4.1. Sickle Cell Diseases
13.4.2. Thalassemia
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Hemoglobinopathy Drugs Market Size and Volume Forecast by Type
13.7.1. Hydroxyurea
13.7.2. Glutamine
13.7.3. Zynteglo
13.7.4. Other
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Hemoglobinopathy Drugs Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Hemoglobinopathy Drugs Market: Market Share Analysis
14.2. Hemoglobinopathy Drugs Distributors and Customers
14.3. Hemoglobinopathy Drugs Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Novartis
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. AstraZeneca
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Bluebird
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Bristol-Myers Squibb
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Emmaus Medical
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Acceleron Pharma
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. HemaQuest Pharmaceuticals
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Eli Lilly and Company
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Celgene
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook